Illumina, Inc. ILMN recently announced the receipt of approval from the China National Drug Administration (CNDA) for its next-generation sequencing (NGS) MiSeq Dx Sequencing System. With this, Illumina is authorized to commercially launch the MiSeqDx Sequencing System in hospitals and other medical institutions for in-vitro diagnostic testing across China.
What is MiSeqDx Sequencing System?
MiSeqDx Sequencing System is a benchtop sequencer which will help medical institutions in developing new clinical assays and will also aid in-vitro diagnostic (IVD) developers in creating accurate diagnostic testing. This NGS system incorporates an easy-to-use workflow and data output to meet the varying needs of clinical labs. Furthermore, integrated software allows run setup, sample tracking, user management, audit trails and data interpretation.
Notably, the MiSeqDx Sequencing System already has received regulatory approval in the United States, Canada, Argentina, European countries accepting the CE-IVD mark, Australia, South Korea, Singapore, Thailand and the Philippines, in the past.
NGS Platform in Focus
Illumina recently announced the acquisition of Edico Genome to strengthen the NGS platform. Per the company, the Edico Genome’s DRAGEN Bio-IT (DRAGEN) platform complements Illumina’s sequencing portfolio and helps in delivering rapid and streamlined output for NGS customers.
The company also recently introduced a second FDA-regulated and CE-IVD marked NGS system — NextSeq 550Dx. The company has received product approval for the NextSeq 550Dx instrument from the Ministry of Food and Drug Safety (MFDS) in South Korea as well.
In April, the company collaborated with Bristol-Myers Squibb Company (BMY) in the field of oncology. Bristol-Myers Squibb will utilize Illumina’s NGS technology to develop and globally commercialize IVD assays to support its oncology portfolio.
Illumina also announced a global strategic partnership with Loxo Oncology to develop and commercialize a multi-gene panel for broad tumor profiling, resulting in a distributable, NGS-based companion diagnostic (CDx) with a pan-cancer indication.
Market Potential
According to Markets and Markets, the global next-generation sequencing market is estimated to reach a worth of $12.45 billion by 2022, at a CAGR of 20.5%. This shows that the approval has come at the right time and will help Illumina cash in on the bountiful NGS market opportunities.
Share Price Performance
Over the past year, Illumina has outperformed its industry. The company has gained 71.5% against the industry’s decline of 12.4%.
.jpg)
Zacks Rank and Other Key Picks
Illumina currently carries a Zacks Rank #1 (Strong Buy).
Other top-ranked stocks in the broader medical space are Integer Holdings Corporation ITGR, Intuitive Surgical ISRG and Masimo Corporation MASI.
Integer Holdings’ expected long-term earnings growth rate is 15%. The stock sports a Zacks Rank #1. You can see the complete list of today’s Zacks #1 Rank stocks here.
Intuitive Surgical’s long-term expected earnings growth rate is 14.7%. The stock carries a Zacks Rank #1.
Masimo’s long-term expected earnings growth rate is 14.8%. The stock has a Zacks Rank #2 (Buy).
Best Electric Car Stock? You'll Never Guess It.
Zacks Research has released a report that may shock many investors. One stock stands out as the best way to invest in the surge to electric cars. And it's not the one you may think!
Much like petroleum 150 years ago, lithium battery power is set to shake the world, creating millionaires and reshaping geo-politics. Soon electric vehicles (EVs) may be cheaper than gas guzzlers. Some are already reaching 265 miles on a single charge. With battery prices plummeting and charging stations set to multiply, revenues that were already at $31 billion in 2016 are expected to blast to over $67 billion by the end of 2022.
See Zacks Best EV Stock Free >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Be the first to comment